- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01907113
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BI 10773 in Type II Diabetes Patients With Different Degrees of Renal Impairment
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a Single 50 mg Dose of BI 10773 in Patients With Different Degrees of Renal Impairment in Comparison to Subjects With Type 2 Diabetes and Normal Renal Function in a Monocentric, Open-label, Parallel-group, Phase 1 Trial
Studieoversigt
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
-
Kiel, Tyskland
- 1245.12.1 Boehringer Ingelheim Investigational Site
-
Neuss, Tyskland
- 1245.12.2 Boehringer Ingelheim Investigational Site
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion criteria:
- Male and female subjects with type 2 diabetes
- Renally impaired male or female subjects
- Age 18 - 75 years
- BMI 18 - 34 kg/m2, at least 45 kg for females (Body Mass Index)
- Signed and dated written informed consent
Exclusion criteria:
- Significant gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders as judged by the investigator.
- Relevant gastrointestinal tract surgery
- Diseases of the central nervous system (such as epilepsy, seizures) or psychiatric disorders or relevant neurological disorders
- History of relevant orthostatic hypotension, fainting spells or blackouts; systolic blood pressure < 100 or > 160 mm Hg, diastolic blood pressure < 60 or > 100 mm Hg, pulse rate < 50 or > 100 1/min
- Chronic or relevant acute infections
- History of allergy/hypersensitivity (including drug allergies) that are deemed relevant to the trial as judged by the investigator
Use within 10 days prior to administration or during the trial of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation. Co medication known to inhibit or induce P-glycoprotein or CYP3A is not allowed. Inhibitors of P-glycoprotein or CYP3A (cytochrom P3A) are e.g.
- protease inhibitors, (e.g. ritonavir, lopinavir nelfinavir)
- azole antimycotics, (itraconazole, ketoconazole, miconazole)
- macrolid antibiotics, (clarithromycin, erythromycin)
- amiodarone, cimetidine, diltiazem, fluvoxamine, mibefradil, nefazodone, verapamil, tacrolimus, quinidine, reserpine, cyclosporine A Inducers of P-gp or CYP3A are e.g. carbamazepine, phenobarbital, phenytoin, rifabutin, ri-fampin, St. John's wort, troglitazone. In dubious cases, a case by case decision will be made after consultation with the sponsor.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: BI 10773 / Group 2
Single Dose Administration (type 2 diabetes and mild renal impairment)
|
oral administration
|
Eksperimentel: BI 10773 / Group 3
Single Dose Administration (type 2 diabetes and moderate renal impairment)
|
oral administration
|
Eksperimentel: BI 10773 / Group 4
Single Dose Administration (severe renal impairment 8)
|
oral administration
|
Eksperimentel: BI 10773 / Group 5
Single Dose Administration (kidney failure)
|
oral administration
|
Eksperimentel: BI 10773 / Group 1
Single Dose Administration (type 2 diabetes and normal renal function)
|
oral administration
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
AUC0-∞ (Area Under the Concentration Time Curve of the Analyte in Plasma Over the Time Interval From 0 to Infinity)
Tidsramme: 1 hour (h) before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration
|
Area under the concentration time curve of the analyte in plasma over the time interval from 0 to infinity.
The areas under the curve were calculated using the linear up/log down algorithm.
If a drug concentration was equal to or higher than the preceding concentration, the linear trapezoidal method was used.
If the drug concentration was smaller than the preceding concentration, the logarithmic method was used.
|
1 hour (h) before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration
|
Cmax (Maximum Concentration of the Analyte in Plasma)
Tidsramme: 1 hour (h) before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration
|
Maximum concentration of Empagliflozin in plasma
|
1 hour (h) before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Time to Maximum Concentration of the Analyte in Plasma
Tidsramme: 1 h before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration
|
Time from last dosing to maximum concentration of Empagliflozin in plasma (tmax)
|
1 h before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration
|
Half-life and Mean Residence Time of the Analyte in Plasma
Tidsramme: 1 h before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration
|
Terminal half-life of Empagliflozin (t1/2) and Mean residence time of Empagliflozin in the body
|
1 h before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration
|
Terminal Rate Constant in Plasma
Tidsramme: 1 h before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration
|
Terminal rate constant in plasma (Lz)
|
1 h before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration
|
Apparent Clearance of the Analyte in the Plasma After Extravascular Administration
Tidsramme: 1 h before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration
|
Apparent clearance of the analyte in the plasma after extravascular administration
|
1 h before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration
|
Apparent Volume of Distribution During the Terminal Phase Lz
Tidsramme: 1 h before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration
|
Apparent volume of distribution during the terminal phase Lz
|
1 h before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration
|
AUC0-tz (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point)
Tidsramme: 1 h before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration
|
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point.
The areas under the curve were calculated using the linear up/log down algorithm.
If a drug concentration was equal to or higher than the preceding concentration, the linear trapezoidal method was used.
If the drug concentration was smaller than the preceding concentration, the logarithmic method was used.
|
1 h before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration
|
Ae0-96 (Amount of Analyte That is Eliminated in Urine Over the Time Interval 0 to 96 h)
Tidsramme: 24-0 h before drug administration and 0-4, 4-8, 8-12, 12-24, 24-36, 36-48, 48-72, 72-96 hours after drug administration
|
Amount of analyte that is eliminated in urine over the time interval 0-96 hours.
|
24-0 h before drug administration and 0-4, 4-8, 8-12, 12-24, 24-36, 36-48, 48-72, 72-96 hours after drug administration
|
fe0-96 (Fraction of Analyte Excreted Unchanged in Urine From Time Points 0 to 96 Hours)
Tidsramme: 24-0 h before drug administration and 0-4, 4-8, 8-12, 12-24, 24-36, 36-48, 48-72, 72-96 hours after drug administration
|
Fraction of analyte excreted unchanged in urine from time point 0-96 hours.
|
24-0 h before drug administration and 0-4, 4-8, 8-12, 12-24, 24-36, 36-48, 48-72, 72-96 hours after drug administration
|
Renal Clearance of the Analyte in Plasma After Extravascular Administration
Tidsramme: 24-0 h before drug administration and 0-4, 4-8, 8-12, 12-24, 24-36, 36-48, 48-72, 72-96 hours after drug administration
|
Renal Clearance of the Analyte in Plasma After Extravascular Administration for time interval 0-96 hours.
|
24-0 h before drug administration and 0-4, 4-8, 8-12, 12-24, 24-36, 36-48, 48-72, 72-96 hours after drug administration
|
%AUCtz-∞ (Percentage of Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From the Time of the Last Quantifiable Data Point Extrapolated to Infinity)
Tidsramme: 1 h before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration
|
Percentage of area under the concentration-time curve of the analyte in plasma over the time interval from the time of the last quantifiable data point extrapolated to infinity
|
1 h before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration
|
Plasma Protein Binding
Tidsramme: 1 h before drug administration and 1:30 and 3:00 h after drug administration
|
Plasma protein binding is the percent of analyte binding to the plasma protein, pre-dose plasma samples were spiked with Empa 1000 nmol/L. The standard deviation is actually the coefficient of variation. |
1 h before drug administration and 1:30 and 3:00 h after drug administration
|
Total Urinary Glucose Excretion (UGE)
Tidsramme: 24-0 h before drug administration and 0-4, 4-8, 8-12, 12-24, 24-36, 36-48, 48-72, 72-96 hours after drug administration (Interval 24-0 h before drug administration only for baseline UGE)
|
Change from baseline in total urinary glucose excretion
|
24-0 h before drug administration and 0-4, 4-8, 8-12, 12-24, 24-36, 36-48, 48-72, 72-96 hours after drug administration (Interval 24-0 h before drug administration only for baseline UGE)
|
Safety: Physical Examination, Vital Signs, ECG and Laboratory Measurements
Tidsramme: Drug administration until end-of-study-examination, 5 days
|
Number of participants with clinically relevant findings in physical examination, Vital Signs, Clinically Significant Abnormalities in Electrocardiogram (ECG) and Significant Changes from Baseline Laboratory Measurements
|
Drug administration until end-of-study-examination, 5 days
|
Assessment of Tolerability by Investigator
Tidsramme: Drug administration until end-of-study-examination, 5 days
|
Tolerability was assessed by the investigator based on adverse events and the laboratory evaluation.
|
Drug administration until end-of-study-examination, 5 days
|
Samarbejdspartnere og efterforskere
Sponsor
Publikationer og nyttige links
Hjælpsomme links
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 1245.12
- 2008-006086-86 (EudraCT nummer: EudraCT)
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Diabetes mellitus, type 2
-
University Hospital Inselspital, BerneAfsluttetType 2 diabetes mellitusSchweiz
-
India Diabetes Research Foundation & Dr. A. Ramachandran...Afsluttet
-
US Department of Veterans AffairsAmerican Diabetes AssociationAfsluttetType 2 diabetes mellitusForenede Stater
-
Dexa Medica GroupAfsluttetType-2 diabetes mellitusIndonesien
-
AstraZenecaRekruttering
-
Daewoong Pharmaceutical Co. LTD.Ikke rekrutterer endnuT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRekrutteringType 2 diabetes mellitus (T2DM)Kina
-
Newsoara Biopharma Co., Ltd.RekrutteringT2DM (Type 2 Diabetes Mellitus)Kina
-
Shanghai Golden Leaf MedTec Co. LtdAktiv, ikke rekrutterendeType 2 diabetes mellitus (T2DM)Kina
-
SanofiAfsluttet
Kliniske forsøg med BI 10773
-
Boehringer IngelheimAfsluttetDiabetes mellitus, type 2Tyskland
-
Boehringer IngelheimEli Lilly and CompanyAfsluttetDiabetes mellitus, type 2Forenede Stater, Argentina, Australien, Østrig, Belgien, Brasilien, Canada, Colombia, Kroatien, Tjekkiet, Danmark, Estland, Frankrig, Georgien, Grækenland, Hong Kong, Ungarn, Indien, Indonesien, Israel, Italien, Japan, Korea, Republikken og mere
-
Boehringer IngelheimEli Lilly and CompanyAfsluttetDiabetes mellitus, type 2Forenede Stater, Argentina, Australien, Canada, El Salvador, Tyskland, Italien, Portugal, Den Russiske Føderation, Spanien, Ukraine
-
Boehringer IngelheimEli Lilly and CompanyAfsluttetDiabetes mellitus, type 2Forenede Stater, Danmark, Frankrig, Irland, Korea, Republikken, Portugal, Det Forenede Kongerige
-
Boehringer IngelheimEli Lilly and CompanyAfsluttetDiabetes mellitus, type 2Forenede Stater, Canada, Kina, Frankrig, Tyskland, Indien, Korea, Republikken, Mexico, Slovakiet, Slovenien, Taiwan, Kalkun
-
Boehringer IngelheimAfsluttet
-
Boehringer IngelheimAfsluttet
-
Boehringer IngelheimAfsluttetDiabetes mellitus, type 2Tyskland
-
Boehringer IngelheimEli Lilly and CompanyAfsluttetDiabetes mellitus, type 2Forenede Stater, Argentina, Australien, Brasilien, Bulgarien, Canada, Colombia, Danmark, Estland, Ungarn, Italien, Libanon, Malaysia, Mexico, Peru, Filippinerne, Polen, Rumænien, Den Russiske Føderation, Spanien, Sverige, Taiwan
-
Boehringer IngelheimAfsluttet